Research Triangle Park, NC-based Viamet Pharmaceuticals in January reported positive results from its Phase 2b randomized controlled trial of VT-1161 for onychomycosis of the large toenail. VT-1161 is a novel, once-weekly, oral antifungal drug. The investigators assigned 259 patients to one of five study arms: 300 mg of VT-1161 once weekly for 12 weeks, then 12 weeks of placebo; 600 mg of VT-1161 once weekly for 12 weeks, followed by 12 weeks of placebo; either 300 or 600 mg of the antifungal agent once weekly for the full 24 weeks; or 24 weeks of once-per-week placebo.
See more here:
Viamet antifungal appears effective, safe